Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prostate specific antigen: utilization modalities and interpretation].

J-M Hannoun-Levi1, A Ginot, J Thariat

  • 1Centre Antoine-Lacassagne, département de radiothérapie, 33, avenue de Valombrose, 06189 Nice cedex, France. jean-michel.hannoun-levi@nice.fnclcc.fr

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|June 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From operating room to radiotherapy planning: A technical innovation in sinonasal oncology.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

REFCOR guidelines for sinonasal adenocarcinoma.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

A review of clinical trial radiotherapy quality assurance: value, evolution and lessons.

Clinical and translational radiation oncology·2026
Same author

REFCOR good practice guidelines for radiotherapy in sinonasal carcinomas and mucosal melanomas.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

REFCOR guidelines for sinus and nasal cavity cancer.

European annals of otorhinolaryngology, head and neck diseases·2026
Same journal

White paper on radiotherapy in France: Ten objectives to strengthen one of the major modalities of cancer treatment.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Factors affecting the stability of deep inspiration breath-holding in radiotherapy for left-sided breast cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Incidence and outcomes of radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Radiotherapy as a curative strategy for primary pleural indolent lymphomas: Analytical guidelines based on literature and an illustrative population-based case series.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Cone-beam computed tomography-based radiomics for tumour regression assessment during radiotherapy of non-small-cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
See all related articles

The prostate specific antigen (PSA) test is a popular screening tool for prostate cancer (PC). Careful analysis of PSA levels, including PSA doubling time and velocity, is crucial for monitoring treatment effectiveness and detecting relapse.

Area of Science:

  • Oncology
  • Biochemistry
  • Urology

Context:

  • Prostate specific antigen (PSA) testing is widely used for prostate cancer (PC) screening and surveillance.
  • Physiological variability necessitates cautious interpretation of PSA test results.
  • PSA monitoring is essential following treatments like surgery or radiation therapy for PC.

Purpose:

  • To highlight the importance of PSA testing in prostate cancer management.
  • To emphasize the need for careful analysis of PSA results due to variability.
  • To underscore the significance of PSA kinetics (doubling time, velocity) in detecting biochemical relapse.

Summary:

  • The prostate specific antigen (PSA) test is a common blood test for prostate cancer (PC) screening and post-treatment surveillance.

Related Experiment Videos

  • PSA results require cautious interpretation due to physiological variability.
  • PSA levels after treatment (surgery, radiation) help confirm biochemical control or relapse.
  • New data on PSA kinetics, such as PSA doubling time and PSA velocity, are vital for managing biochemical relapse.

    • Impact:

    • Improved understanding of PSA test utility in clinical practice.
    • Enhanced patient monitoring and management strategies for prostate cancer.
    • Potential for earlier detection of biochemical relapse, leading to timely intervention.